Unknown

Dataset Information

0

Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.


ABSTRACT:

Purpose

This randomized, multicenter, open-label, phase Ib/II study assessed durvalumab and tremelimumab in combination or as monotherapy for chemotherapy-refractory gastric cancer or gastroesophageal junction (GEJ) cancer.

Patients and methods

Second-line patients were randomized 2:2:1 to receive durvalumab plus tremelimumab (arm A), or durvalumab (arm B) or tremelimumab monotherapy (arm C), and third-line patients received durvalumab plus tremelimumab (arm D). A tumor-based IFN? gene signature was prospectively evaluated as a potential predictive biomarker in second- and third-line patients receiving the combination (arm E). The coprimary endpoints were objective response rate and progression-free survival (PFS) rate at 6 months.

Results

A total of 113 patients were treated: 6 in phase Ib and 107 (arm A, 27; arm B, 24; arm C, 12; arm D, 25; arm E, 19) in phase II. Overall response rates were 7.4%, 0%, 8.3%, 4.0%, and 15.8% in the five arms, respectively. PFS rates at 6 months were 6.1%, 0%, 20%, 15%, and 0%, and 12-month overall survival rates were 37.0%, 4.6%, 22.9%, 38.8%, and NA, respectively. Treatment-related grade 3/4 adverse events were reported in 17%, 4%, 42%, 16%, and 11% of patients, respectively.

Conclusions

Response rates were low regardless of monotherapy or combination strategies. No new safety signals were identified. Including use of a tumor-based IFN? signature and change in baseline and on-treatment circulating tumor DNA are clinically feasible and may be novel strategies to improve treatment response in this difficult-to-treat population.

SUBMITTER: Kelly RJ 

PROVIDER: S-EPMC7748730 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Purpose</h4>This randomized, multicenter, open-label, phase Ib/II study assessed durvalumab and tremelimumab in combination or as monotherapy for chemotherapy-refractory gastric cancer or gastroesophageal junction (GEJ) cancer.<h4>Patients and methods</h4>Second-line patients were randomized 2:2:1 to receive durvalumab plus tremelimumab (arm A), or durvalumab (arm B) or tremelimumab monotherapy (arm C), and third-line patients received durvalumab plus tremelimumab (arm D). A tumor-based IFNγ  ...[more]

Similar Datasets

| S-EPMC5827797 | biostudies-literature
| S-EPMC5224844 | biostudies-literature
| S-EPMC9524015 | biostudies-literature
| S-EPMC7496223 | biostudies-literature
| S-EPMC6570680 | biostudies-literature
| S-EPMC10425436 | biostudies-literature
| S-EPMC10201153 | biostudies-literature
| S-EPMC7398745 | biostudies-literature
| S-EPMC4815769 | biostudies-literature
| S-EPMC2903332 | biostudies-literature